AzTrials
AzTrials

TraumaPSCATNCT01713205

Prediction Study of Complications After Severe Trauma

An observational study of Trauma and Sepsis, run by Jiang Jianxin at 6 sites in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate a clinically and economically most effective diagnostic algorithm for prediction of post-traumatic complications in a multicenter sample of severe trauma patients. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
How many people
3,500 participants
Where
6 sitesChina
Study dates
Oct 2012to Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adult severe trauma patients with no serious co-morbidity

Who may be able to join

  • age> 16 years old and <65 years old
  • severe trauma patients (AIS ≧3 or ISS≧16)
  • admission within 48 hours after injury
  • given and signed informed consent

Who cannot join

  • died within 48h after injury
  • being pregnant or lactating
  • chronic organ dysfunction comorbidities
  • long-term anticoagulant therapy before injury
  • presence of immunosuppression before injury

Trial locations and contacts

6 sites in 1 country.

Anqiang Zhang, MD contact

+86-23-68757402

zhanganqiang@126.com

6 sites in 1 country

China6 sites, 6 recruiting
  • Chongqing Emergency Medical Center

    Chongqing, 400014

    Dingyuan Du, MD,PhD, +86-23-63692110, dudingyuan@qq.com.cn

    Dingyuan Du, MD,PhD

    Recruiting
  • Daping Hospital / Research Institute of Surgery, the Third Military Medical University

    Chongqing, 400042

    Lianyang Zhang, MD,PhD, +86-23-68757991, hapzhangly@163.com

    Lianyang Zhang, MD,PhD

    Recruiting
  • Department of Emergency Surgery, The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, 550004

    Jin Deng, MD, +86-851-86771474, Dengjin6067@126.com

    Recruiting
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, 310009

    Mao Zhang, MD,PhD, +86-571-87783803, zmhz@hotmail.com

    Mao Zhang, MD,PhD

    Recruiting
  • Kunming General Hospital of Chengdu Military Region

    Kunming, Yunnan, 650032

    Jiang Hao, MD,PhD, +86-871-64774999, kmlmhj@sina.com

    Jiang Hao, MD,PhD

    Recruiting
  • Tongji Hospital, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030

    Xiangjun Bai, MD,PhD, +86-27-83663669, baixiangjun@hotmail.com

    Xiangjun Bai, MD,PhD

    Recruiting

Other trials in China

About this study

Official title: Identifying Severe Trauma Patients at High Risk of Post-traumatic Complications

The purpose of this study is to evaluate a clinically and economically most effective diagnostic algorithm for prediction of post-traumatic complications in a multicenter sample of severe trauma patients.

Read the detailed description

Trauma is a major public health problem worldwide, ranking as the fourth leading cause of death. One of the most serious complications of major trauma is sepsis, which often induces sequential multiple organ dysfunction syndrome (MODS). There were still no specific biomarkers to predict the susceptibility of complications and outcomes, which leading to the limited prevention methods and the high mortality rate of severe trauma patients. Previous studies from our and other group have found some sepsis and MODS predictors, including genetic polymorphisms, serum cytokines and cell-surface markers. The purposes of this multi-center observational study is to select biomarkers and evaluate a clinically and economically most effective diagnostic algorithm for prediction of complications in severe trauma patients.

Keywords
trauma ; sepsis; Multiple Organ Dysfunction Syndrome; Prediction; risk
Medical subject headings
Wounds and Injuries, Sepsis, Multiple Organ Failure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. morbidity rate of complications after trauma (including sepsis and MODS)

    Measured: patients will be followed for the duration of hospital stay, an expected average of 3 weeks

Secondary outcomes (1)
  1. survival

    Measured: witnin 30 days and 60 days after injury

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Oct 2012 (estimated)
  2. Study startOct 2012
  3. Primary completionDec 2023 (estimated)
  4. Study completionDec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
3,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01713205
Sponsor's protocol ID
Jiang-2012BAI11B01
Other IDs
2012BAI11B01
Acronym
PSCAT
Status last verified
Jul 2022
First submitted
18 Oct 2012
Last updated
1 Aug 2022
Results posted
No
Data monitoring committee
Yes

Publications

  • Gu W, Jiang J. Genetic polymorphisms and posttraumatic complications. Comp Funct Genomics. 2010;2010:814086. doi: 10.1155/2010/814086. Epub 2011 Jan 11.

    PubMed 21274447
  • Gu W, Zeng L, Zhang LY, Jiang DP, Du DY, Hu P, Wang HY, Liu Q, Huang SN, Jiang JX. Association of interleukin 4 -589T/C polymorphism with T(H)1 and T(H)2 bias and sepsis in Chinese major trauma patients. J Trauma. 2011 Dec;71(6):1583-7. doi: 10.1097/TA.0b013e3182115034.

    PubMed 21460743
  • Chen KH, Zeng L, Gu W, Zhou J, Du DY, Jiang JX. Polymorphisms in the toll-like receptor 9 gene associated with sepsis and multiple organ dysfunction after major blunt trauma. Br J Surg. 2011 Sep;98(9):1252-9. doi: 10.1002/bjs.7532. Epub 2011 Jun 1.

    PubMed 21633947
  • Zeng L, Zhang AQ, Gu W, Chen KH, Jiang DP, Zhang LY, Du DY, Hu P, Huang SN, Wang HY, Jiang JX. Clinical relevance of single nucleotide polymorphisms of the high mobility group box 1 protein gene in patients with major trauma in southwest China. Surgery. 2012 Mar;151(3):427-36. doi: 10.1016/j.surg.2011.07.075. Epub 2011 Nov 1.

    PubMed 22047946
  • Zhang AQ, Zeng L, Gu W, Zhang LY, Zhou J, Jiang DP, Du DY, Hu P, Yang C, Yan J, Wang HY, Jiang JX. Clinical relevance of single nucleotide polymorphisms within the entire NLRP3 gene in patients with major blunt trauma. Crit Care. 2011;15(6):R280. doi: 10.1186/cc10564. Epub 2011 Nov 23.

    PubMed 22112657
  • Zeng L, Gu W, Zhang AQ, Zhang M, Zhang LY, Du DY, Huang SN, Jiang JX. A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma. Ann Surg. 2012 Jan;255(1):147-57. doi: 10.1097/SLA.0b013e3182389515.

    PubMed 22167001
  • Zeng L, Zhang AQ, Gu W, Zhou J, Zhang LY, Du DY, Zhang M, Wang HY, Jiang JX. Identification of haplotype tag SNPs within the whole myeloid differentiation 2 gene and their clinical relevance in patients with major trauma. Shock. 2012 Apr;37(4):366-72. doi: 10.1097/SHK.0b013e3182498c8f.

    PubMed 22266968
  • Zhang AQ, Gu W, Zeng L, Zhang LY, Du DY, Zhang M, Hao J, Yue CL, Jiang J. Genetic variants of microRNA sequences and susceptibility to sepsis in patients with major blunt trauma. Ann Surg. 2015 Jan;261(1):189-96. doi: 10.1097/SLA.0000000000000687.

    PubMed 24743625
  • Zeng L, Du J, Gu W, Zhang AQ, Wang HY, Wen DL, Qiu L, Yang XT, Sun JH, Zhang M, Hao J, Jiang JX. Rs1800625 in the receptor for advanced glycation end products gene predisposes to sepsis and multiple organ dysfunction syndrome in patients with major trauma. Crit Care. 2015 Jan 9;19(1):6. doi: 10.1186/s13054-014-0727-2.

    PubMed 25572180
  • Pan W, Zhang AQ, Gu W, Gao JW, Du DY, Zhang LY, Zeng L, Du J, Wang HY, Jiang JX. Identification of haplotype tag single nucleotide polymorphisms within the nuclear factor-kappaB family genes and their clinical relevance in patients with major trauma. Crit Care. 2015 Mar 20;19(1):95. doi: 10.1186/s13054-015-0836-6.

    PubMed 25880845
  • Gao JW, Zeng L, Zhang AQ, Wang X, Pan W, Du DY, Zhang LY, Gu W, Jiang JX. Identification of Haplotype Tag Single-Nucleotide Polymorphisms within the PPAR Family Genes and Their Clinical Relevance in Patients with Major Trauma. Int J Environ Res Public Health. 2016 Mar 26;13(4):374. doi: 10.3390/ijerph13040374.

    PubMed 27023591
  • Zhang H, Lu Y, Sun G, Teng F, Luo N, Jiang J, Wen A. The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma. Crit Care. 2017 Jul 6;21(1):171. doi: 10.1186/s13054-017-1757-3.

    PubMed 28679406
  • Zhang A, Gu W, Lu H, Zeng L, Zhang L, Du D, Hao J, Wen D, Wang X, Jiang J. Genetic contribution of suppressor of cytokine signalling polymorphisms to the susceptibility to infection after traumatic injury. Clin Exp Immunol. 2018 Oct;194(1):93-102. doi: 10.1111/cei.13160. Epub 2018 Sep 9.

    PubMed 29920655
  • Wang J, Wen D, Zeng S, Du J, Cui L, Sun J, Chen G, Zeng L, Du D, Zhang L, Deng J, Jiang J, Zhang A. Cytokine Biomarker Phenotype for Early Prediction and Triage of Sepsis in Blunt Trauma Patients. J Surg Res. 2023 Mar;283:824-832. doi: 10.1016/j.jss.2022.10.059. Epub 2022 Dec 5.

    PubMed 36915009
  • Sun J, Zhang H, Liu D, Cui L, Wang Q, Gan L, Wen D, Wang J, Du J, Huang H, Zhang A, Deng J, Jiang J, Zeng L. A Functional Variant of CXCL16 Is Associated With Predisposition to Sepsis and MODS in Trauma Patients: Genetic Association Studies. Front Genet. 2021 Sep 3;12:720313. doi: 10.3389/fgene.2021.720313. eCollection 2021.

    PubMed 34539750

Questions about this trial

What is this clinical trial studying?

An observational study of Trauma and Sepsis, run by Jiang Jianxin at 6 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anqiang Zhang, MD (+86-23-68757402, zhanganqiang@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

morbidity rate of complications after trauma (including sepsis and MODS) (time frame: patients will be followed for the duration of hospital stay, an expected average of 3 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01713205, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in